pioglitazone has been researched along with Carcinogenesis in 3 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Carcinogenesis: The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In LNCaP, a human androgen-dependent prostate cancer cell line, PGZ also inhibited cyclin D1 expression and the activation of both p38 MAPK and NFκB." | 5.43 | Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis. ( Kato, H; Kobayashi, M; Kuno, T; Mori, Y; Nagano, A; Nagayasu, Y; Naiki-Ito, A; Suzuki, S; Takahashi, S, 2016) |
| "Furthermore, treating breast cancer cells with pioglitazone that stabilizes the 3Cys-1His cluster of NAF-1 results in a similar effect on mitochondrial iron and reactive oxygen species accumulation." | 1.43 | Breast cancer tumorigenicity is dependent on high expression levels of NAF-1 and the lability of its Fe-S clusters. ( Bai, F; Darash-Yahana, M; Geiger, T; Jennings, PA; Karmi, O; Lu, M; Mittler, R; Nechushtai, R; Onuchic, JN; Pikarsky, E; Pozniak, Y; Sohn, YS; Song, L; Tamir, S, 2016) |
| "In LNCaP, a human androgen-dependent prostate cancer cell line, PGZ also inhibited cyclin D1 expression and the activation of both p38 MAPK and NFκB." | 1.43 | Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis. ( Kato, H; Kobayashi, M; Kuno, T; Mori, Y; Nagano, A; Nagayasu, Y; Naiki-Ito, A; Suzuki, S; Takahashi, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sohn, YS | 2 |
| Tamir, S | 2 |
| Song, L | 2 |
| Michaeli, D | 1 |
| Matouk, I | 1 |
| Conlan, AR | 1 |
| Harir, Y | 1 |
| Holt, SH | 1 |
| Shulaev, V | 1 |
| Paddock, ML | 1 |
| Hochberg, A | 1 |
| Cabanchick, IZ | 1 |
| Onuchic, JN | 2 |
| Jennings, PA | 2 |
| Nechushtai, R | 2 |
| Mittler, R | 2 |
| Darash-Yahana, M | 1 |
| Pozniak, Y | 1 |
| Lu, M | 1 |
| Karmi, O | 1 |
| Bai, F | 1 |
| Pikarsky, E | 1 |
| Geiger, T | 1 |
| Suzuki, S | 1 |
| Mori, Y | 1 |
| Nagano, A | 1 |
| Naiki-Ito, A | 1 |
| Kato, H | 1 |
| Nagayasu, Y | 1 |
| Kobayashi, M | 1 |
| Kuno, T | 1 |
| Takahashi, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone, and Incretin Based Therapy[NCT02882477] | Phase 2/Phase 3 | 20 participants (Anticipated) | Interventional | 2016-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for pioglitazone and Carcinogenesis
| Article | Year |
|---|---|
NAF-1 and mitoNEET are central to human breast cancer proliferation by maintaining mitochondrial homeostasis and promoting tumor growth.
Topics: Animals; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Fema | 2013 |
Breast cancer tumorigenicity is dependent on high expression levels of NAF-1 and the lability of its Fe-S clusters.
Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; | 2016 |
Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis.
Topics: Adenocarcinoma; Animals; Body Weight; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Disease | 2016 |